

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

MYLAN PHARMACEUTICALS INC. and PFIZER, Inc.,  
Petitioners,

v.

SANOFI-AVENTIS DEUTSCHLAND GMBH,  
Patent Owner

---

Case No. IPR2018-01676<sup>1</sup>  
U.S. Patent No. 8,603,044

---

**PATENT OWNER'S OBSERVATIONS ON THE  
CROSS-EXAMINATION OF MR. KARL LEINSING**

---

<sup>1</sup> Pfizer Inc., who filed a petition in IPR2019-00978, has been joined as petitioner in this proceeding.

## EXHIBIT LIST

Exhibit #	Description
2001	Press Release, “Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products”, Feb. 13, 2013 (PR Newswire), available at <a href="http://newsroom.mylan.com/press-releases?item=122834">http://newsroom.mylan.com/press-releases?item=122834</a>
2002	Press Release, “Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®”, Sept. 16, 2014 (PR Newswire), available at <a href="http://newsroom.mylan.com/press-releases?item=123251">http://newsroom.mylan.com/press-releases?item=123251</a>
2003	Press Release, “Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions”, June 10, 2017 (PR Newswire), available at <a href="http://newsroom.mylan.com/2017-06-10-Mylan-and-Biocon-Present-Clinical-Data-on-Insulin-Glargine-at-the-American-Diabetes-Associations-77th-Scientific-Sessions">http://newsroom.mylan.com/2017-06-10-Mylan-and-Biocon-Present-Clinical-Data-on-Insulin-Glargine-at-the-American-Diabetes-Associations-77th-Scientific-Sessions</a>
2004	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH v. Eli Lilly and Company</i> , C.A. No. 1-14-cv-00113-RGA (D. Del), Dkt. No. 1
2005	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie v. Merck Sharp &amp; Dohme Corp.</i> , C.A. No. 1-16-cv-00812-RGA (D. Del), Dkt. No. 1
2006	Stipulation and Proposed Order, <i>Sanofi-Aventis U.S. LLC v. Mylan, N.V.</i> , Civil Action No. 17-9105-SRC-SLW (D.N.J. Feb 5, 2018), Dkt. No. 45
2007	Complaint for Patent Infringement, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J. Oct. 24, 2017), Dkt. No. 1
2008	Excerpts from Defendants’ Invalidation Contentions, dated Jan. 25, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2009	Excerpts from Mylan GMBH’s Amended Invalidation Contentions, dated April 25, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2010	Excerpts from Mylan GMBH’s Exhibit C to Amended Invalidation Contentions, dated April 25, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)

Exhibit #	Description
2011	Aug. 13, 2018 Service of Sanofi's Responses to Mylan's Amended Contentions, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2012	MP4 file of Sanofi's Patented Pen animation
2013	Excerpt from Defendants' opening claim construction brief, dated October 12, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2014	Memorandum Opinion, <i>Sanofi-Aventis U.S. LLC v. Merck Sharp &amp; Corp.</i> , Case No. 16-cv-812-RGA (D. Del.), Dkt. No. 192
2015	International Patent WO 99/3855
2016	Excerpt from Joint claim construction statement, Ex. A, dated October 8, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2017	Animation depicting Møller's first embodiment
2018	Animation depicting Møller's second embodiment
2019	Defendants' Opposition to Plaintiffs' Motion to Stay dated Nov. 22, 2017, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 1:17-cv-00181-IMK (N.D. Va.), Dkt. No. 44
2020	Joint Proposed Discovery Plan dated Dec. 14, 2017, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.)
2021	Letter from A. Calmann to Judge Waldor dated Apr. 24, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-cv-09105-SRC-CLW (D.N.J.), Dkt. No. 90
2022	Motion to Expedite Defendants' Motion Requesting an Expedited Scheduling Conference dated Nov. 22, 2017, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 1:17-cv-00181-IMK (N.D. Va.), Dkt. No. 46
2023	Initial Planning Meeting Report and Discovery Proposals dated Dec. 22, 2017, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 1:17-cv-00181-IMK (N.D. Va.), Dkt. No. 61
2024	Transcript of Motion / Scheduling Conference dated Jan. 3, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 1:17-cv-00181-IMK (N.D. Va.), Dkt. No. 64
2025	Excerpts from Transcript, Conference Call dated Aug. 2, 2018, <i>Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al.</i> , Case No. 2:17-

Exhibit #	Description
	cv-09105-SRC-CLW (D.N.J.) (confidentiality designation removed)
2026	Report of the Local Patent Rules Committee, Explanatory Notes for 2016 Amendments
2027	Transcript, Conference Call for Case IPR2018-01675, -01676, -01678, -01680 (P.T.A.B. Feb. 5, 2019)
2028-	<i>Reserved</i>
2100	Leinsing Deposition Exhibit 2100: Thomas van der Burg, <i>Injection Force of SoloSTAR® Compared with Other Disposable Insulin Pen Devices at Constant Volume Flow Rates</i> , J. of Diabetes Sci. and Tech., Vol. 5, Issue 1, 150-155 (Jan. 2001)
2101	Leinsing Deposition Exhibit 2101: Estelle Davis, et. al., <i>An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen®</i> , Med. Devices: Evidence & Research, 41-50 (2010:3)
2102	Leinsing Deposition Exhibit 2102: Hand drawings
2103	Leinsing Deposition Exhibit 2103: Annotations of Figures 6-15 of Burroughs
2104	Leinsing Deposition Exhibit 2104: Annotations of Figures 5-8 of the 486 Patent
2105	Leinsing Deposition Exhibit 2105: Hand drawings
2106	Leinsing Deposition exhibit 2106: Annotations of Figures 11 and 12 of Giambattista
2107	Declaration of Alexander Slocum, Ph.D.
2108	Curriculum Vitae of Alexander Slocum, Ph.D.
2109	<i>Reserved</i>
2110	<i>Reserved</i>
2111	Declaration of Dr. Robin S. Goland
2112	Curriculum Vitae of Dr. Robin S. Goland
2113	Bradley M. Wright et al., <i>A Review Of Insulin Pen Devices And Use In The Elderly Diabetic Population</i> , 3 Clinical Medicine Insights: Endocrinology & Diabetes 54-63 (2010)
2114	Teresa L. Pearson, <i>A-Practical-Review-of-Insulin-Pen-Devices</i> , EMJ Diabet., 58-64 (2014:2)

Exhibit #	Description
2115	Arthritis & Diabetes, <i>What do diabetes and arthritis have in common? Plenty.</i> , <a href="https://www.arthritis.org/living-with-arthritis/comorbidities/diabetes-and-arthritis/">https://www.arthritis.org/living-with-arthritis/comorbidities/diabetes-and-arthritis/</a>
2116	Andreas Bode, <i>Development of the SoloSTAR insulin pen device design verification and validation</i> , 6 Expert Opinion on Drug Delivery 103-112 (2008)
2117	Sanofi's Patented Pen animation
2118	John Carter, <i>Usability, Participant Acceptance, and Safety of a Prefilled Insulin Injection Device in a 3-Month Observational Survey in Everyday Clinical Practice in Australia</i> , <i>J. Diabetes Sci &amp; Tech.</i> , Vol. 3, Issue 6, 1425-1438 (Nov. 2009)
2119	Sherwyn Schwartz, <i>Correct Use of a New Reusable Insulin Injection Pen by Patients with Diabetes: A Design Validation Study</i> , 4 <i>J. Diabetes Sci. and Tech.</i> 1229-1235 (2010)
2120	Estelle Davis, et. al., <i>An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen®</i> , <i>Med. Devices: Evidence &amp; Research</i> , 41-50 (2010:3)
2121	DBA Design Effectiveness Awards 2009
2122	SoloSTAR Disposable Pen Injector (The Grand Prix Oct. 22, 2009)
2123	Arnd Friedrichs et al., <i>Dose Accuracy and Injection Force of Different Insulin Glargine Pens</i> , 7 <i>J. Diabetes Sci. and Tech.</i> 1346-1353 (2013)
2124	Stacey A. Seggelke et al., <i>Effect of Glargine Insulin Delivery Method (Pen Device Versus Vial/Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes</i> , 20 <i>ENDOCRINE PRACTICE</i> , 536, 536, 538–539 (2014)
2125	Julia Pfutzner et al., <i>Evaluation of Dexterity in Insulin-Treated Patients with Type 1 and Type 2 Diabetes Mellitus</i> , 5 <i>J. Diabetes Sci. and Tech.</i> 158-165 (2011)
2126	Jerome S. Fischer et al., <i>United States Patient Preference and Usability for the New Disposable Insulin Device Solostar® versus Other Disposable Pens</i> , 2 <i>JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY</i> 1157-1160 (2008)
2127	U.S. Provisional Patent Application 60/073820

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.